

## Eylea® (aflibercept) Injection

When requesting Eylea® (aflibercept), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications or approved off-label compendial use and meet the specific coverage guidelines for the covered indication.

### FDA-Approved Indications

Eylea is indicated for the treatment of patients with:

- Neovascular (wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic macular edema (DME)
- Diabetic retinopathy (DR)

### Approved Off-Label Compendial Uses

- Other neovascular ophthalmic conditions (e.g., neovascular glaucoma, retinopathy of prematurity, sickle cell neovascularization, choroidal neovascular conditions)

### Coverage Guidelines

For all approved indications the individual must meet the following criteria for approval:

- Eylea is administered by or under the supervision of an ophthalmologist

**Approval duration: 12 months**

### Dosing Recommendations

#### **Neovascular (Wet) Age-Related Macular Degeneration (AMD)**

The recommended dose is 2 mg administered by intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg via intravitreal injection once every 8 weeks.

#### **Macular Edema Following Retinal Vein Occlusion (RVO)**

The recommended dose is 2 mg administered by intravitreal injection once every 4 weeks.

#### **Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)**

The recommended dose is 2 mg administered by intravitreal injection every 4 weeks for

the first 5 injections followed by 2 mg via intravitreal injection once every 8 weeks.

1. Eylea® injection [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; June 2021.
2. Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. *Expert Opin Investig Drugs*. 2009;18(5):637-646.
3. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. *Surv Ophthalmol*. 2011;56(2):95-113.
4. Kinnunen K, Ylä-Herttua S. Vascular endothelial growth factors in retinal and choroidal neovascular diseases. *Ann Med*. 2012;44(1):1-17.
5. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. *Curr Opin Ophthalmol*. 2010;21(2):112-117.